MIRUM PHARMACEUTICALS, INC. (MIRM)
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
📈 **POSITIVE** • High confidence analysis (88%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business